Year: 2022

Pixium Vision announces participation in investor conferences and events in October 2022 Paris, France, October 4, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that senior management will participate in the following investor events in October 2022:Biotech Agora, October 12, Paris Lloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer will host an investor cocktail reception in Paris, held in French. Participation is by invitation only.HealthTech Innovation Days, October 13 – 14, ParisLloyd Diamond, Chief Executive Officer, and Offer Nonhoff, Chief Financial Officer will attend in person. Registration...

4 October 2022, 7:00am, Antwerp, Belgium: The Rating Agency Fitch Ratings (‘Fitch’) has reaffirmed the credit rating for VGP NV (‘VGP’ or ‘the Group’) with its Long-Term Issuer Default Rating (IDR) and senior unsecured rating reaffirmed at ‘BBB-‘. The Outlook on the rating is Stable. Fitch sees the statement by VGP and Allianz, as issued last Friday, in relation to the postponement of the seed portfolio closing for the Europa joint venture as a market-induced pause, not cessation of JV transfers. VGP has adequate liquidity to fund 2H22 and FY23 committed capex (much of it pre-let) even if monetisation of assets to JVs are postponed. The pro forma €730 million end-1H22 cash includes the €1 billion of bond proceeds raised in January 2022 (at a blended 2% fixed coupon) and the completed JV closures in 1H22 and July 2022. Additionally,...

multitude_bank_logo_greenMultitude SE: Announcement of rebranding subsidiary, Ferratum Bank p.l.c., to Multitude Bank p.l.c. Helsinki, 04 October 2022 – Multitude SE (“Multitude” or “the Group”) announces its subsidiary, Ferratum Bank p.l.c., to be rebranded and renamed to Multitude Bank p.l.c. (“the Bank”). Renaming the Bank is part of a broader rebranding by Multitude SE, which was, until June 2021, called Ferratum Oyj. The new name represents the Bank’s growing national and international presence and allows for easier association with the Group. Multitude Bank, with a full European banking license, is the regulatory backbone of Multitude Group and acts as a key service provider to the customers of Multitude’s growth platform. The growth platform enables businesses to grow and scale faster through its centralised core operations....

In light of the Norwegian government’s proposal for a 40% resource tax on Norwegian aquaculture, and a resulting total tax of 62%, Mowi is cancelling its acquisition of 914 tonnes MAB for a total value of NOK 183 million. The government’s tax proposal means that Mowi can no longer justify the purchase price. Mowi respectfully advises the government to reconsider its resource tax proposal. The aquaculture industry is of great importance for the future of Norway and it is in the nation’s best interests to see it grow, however, this proposal will severely damage the ability and willingness to make investments. A tax rate of 62% will put an end to many significant investment plans along the Norwegian coast, leading not only to less employment locally but also to a massive diversion of funds away from coastal communities. Mowi is a global company...

The center will be equipped with a Cyclone® KIUBE offering the highest production capacity with a PET cyclotron. Louvain-La-Neuve, Belgium, October 4, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, Novatec International and ElsMed Healthcare Solutions, the leading Israeli medical-technological company, announced today that they have signed a contract for the installation of an integrated radiopharmaceutical production facility in Tbilisi, Georgia. The project will be the first of its kind in Georgia and includes the construction of an ultra-modern radiopharmaceutical facility equipped with the latest technologies such as the IBA’s Cyclone® KIUBE and Synthera®+ platform. The center will produce various types...

Notice to the Shareholders of AB Linas Agro Group Vilnius, 4 October 2022Hereby we announce the Annual General Meeting of Shareholders (hereinafter – the Meeting) of AB Linas Agro Group, registered address Subačiaus St. 5, Vilnius, Lithuania, code 148030011, (hereinafter – the Company) is convened.The date, time, and venue of the Meeting – 28 October 2022 at 10.00 a.m., Hotel PACAI, Conference Hall (MANSION – EST.1677 – HOTEL, Didžioji St. 7, Vilnius, Lithuania).The accounting day of the Meeting is 21 October 2022. Only the persons who are the shareholders of the Company at the end of the Accounting day of the Meeting shall have the right to attend and vote at the Meeting.The Rights Accounting day is 15 November 2022. Only the persons who are the shareholders of the Company at the end of the Rights Accounting day shall have proprietary...

SIKA CAPITAL MARKETS DAY: INNOVATING TO ACHIEVE NET ZERO – STRATEGIC ATTRACTIVENESS OF MBCC ACQUISITION CONFIRMED The motto of Sika Capital Markets Day 2022, which takes place in Zurich today, is “Our Path to Net Zero”. Sika’s management team outlines the strategy that allows the company to maintain a high level of growth while achieving its net zero targets by 2050. In a presentation delivered to a 200-plus audience, CEO Thomas Hasler confirms the strategic attractiveness of the MBCC acquisition, and revises growth expectations upward for 2022. Sustainability has been a key factor in Sika’s corporate strategy for over a decade. With its powerful capacity for innovation, Sika develops a range of sustainable solutions for the construction industry, as well as industrial applications for the automotive and other industries. The company is...

RECORD FULL-YEAR RESULT – STRONG SEASON EXPECTED Fourth QuarterNet sales for the fourth quarter were SEK 224 (184) million, an increase of SEK 40 million (22 percent) compared with the previous year. Profit/loss after tax for the fourth quarter was SEK -212 (80) million, a decline of SEK 292 million (364 percent) compared with the previous year, which was positively affected by a capital gain of SEK 198 million on property transactions. Earnings per share amounted to SEK -2.70 (-0.87).Full YearNet sales for the full year were SEK 4,092 (2,689) million, an increase of SEK 1,404 million (52 percent) compared with the previous year. Profit after tax was SEK 665 (234) million, an increase of SEK 431 million (184 percent) compared with the previous year. Earnings per share amounted to SEK 8.50 (3.04), an increase of 180 percent. The Board...

Vancouver, B.C., Oct. 03, 2022 (GLOBE NEWSWIRE) — Origin Therapeutics Holdings Inc. (CSE:ORIG) (the “Company” or “Origin Therapeutics”) announces that Michael Young has resigned as a director of the Company in order to focus on his other businesses. The Company thanks Mr. Young for his contribution and services and wishes him well on his future endeavours. About Origin Therapeutics Origin Therapeutics is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Learn more at www.originpsychedelics.com...